Dr Hank Mansbach joins Medivation
This article was originally published in Scrip
Dr Hank Mansbach has been named vice-president of medical affairs at Medivation (US). He will lead the company's medical affairs activities for Dimebon (latrepirdine), its Phase III candidate for the treatment of Alzheimer's and Huntington diseases, and MDV3100, which is in Phase III development for the treatment of advanced prostate cancer and has just been licensed to Astellas. Dr Mansbach is a neurologist with more than 10 years' drug development experience, having previously served as senior vice-president and head of global drug development at Valeant Pharmaceuticals.